CALCR — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL6176082	0.54	17/20
SCHEMBL12428852	0.57	16/20
SCHEMBL13356192	0.44	16/20
SCHEMBL12984646	0.63	15/20
SCHEMBL10066203	0.60	15/20
SCHEMBL5315503	0.59	15/20
SCHEMBL5315506	0.59	15/20
SCHEMBL5578209	0.59	15/20
SCHEMBL5578210	0.59	15/20
SCHEMBL5311106	0.57	15/20
SCHEMBL5311116	0.57	15/20
SCHEMBL11116638	0.53	15/20
SCHEMBL11116645	0.53	15/20
SCHEMBL8624738	0.51	15/20
SCHEMBL8624746	0.51	15/20
SCHEMBL9081658	0.50	15/20
SCHEMBL10494174	0.66	14/20
SCHEMBL9292957	0.53	13/20
SCHEMBL8973444	0.53	13/20
SCHEMBL13120983	0.52	13/20

Clinical trials — most relevant to CALCR by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Novel Combination Therapy for Osteoporosis in Men	PHASE4	ACTIVE_NOT_RECRUITING
The Study of Efficacy and Safety of REGPARA Drug in Dialysis Patients Have High Blood Levels of Parathyroid	PHASE4	COMPLETED
Efficacy of Cinacalcet in the Control of Primary Hyperparathyroidism	PHASE4	COMPLETED
Hypersensitivity to CGRP as a Predictive Biomarker of Migraine Prevention With Erenumab	PHASE4	UNKNOWN
The Immune and Clinical Impacts of Vitamin D in Patients With Chronic Musculo-skeletal Pain	PHASE4	UNKNOWN
Treatment of Primary Hyperparathyroidism With Denosumab and Cinacalcet.	PHASE3	COMPLETED
Functional Yogurt Powder Effect on Bone Health Biomarkers	PHASE3	COMPLETED
The Nordic Chronic Migraine Trial of CGRP Monoclonal Antibody and Onabotulinumtoxin A Dual Therapy Compared to CGRP mAbs Monotherapy	PHASE3	RECRUITING
Risedronate In The Prevention Of Osteoporosis In Osteopenic Postmenopausal Women	PHASE3	COMPLETED
A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism	PHASE2	COMPLETED
Comparison Study of PTHrP and PTH to Treat Osteoporosis	PHASE2	COMPLETED
Effect of Cinacalcet on Parathyroid Hormone Secretion in Children and Adolescents With Hypophosphatemic Rickets	PHASE1	COMPLETED
PTHrP(1-36) IV Dose Escalation Study	PHASE1	WITHDRAWN
Procalcitonin Increase Identifies Critically Ill Patients at High Risk of Mortality	nan	COMPLETED
Procalcitonin in Diagnosis of Sepsis in Critically Ill Patient	nan	UNKNOWN
Diagnostic and Prognostic Value of Serial Procalcitonin (PCT) Measurements in Critically Ill Patients	nan	COMPLETED
Longitudinal Analysis of Amylin Levels in Migraine Patients Undergoing an Anti- CGRP/CGRPr Treatment	nan	NOT_YET_RECRUITING
Clinical Characteristics and Pathophysiology of Post-Traumatic Headache	nan	COMPLETED
Evaluation of Microbial and Endocrinological Parameters in Dialysis Patients With Sepsis	nan	RECRUITING
Parathyroid Hormone (PTH) Homeostasis in Bartter Syndrome	nan	UNKNOWN
Regulation of Vitamin D Receptor (VDR),Calcium Sensing Receptor (CaSR), Cyclin D1,Ki67 and Proliferating Cell Nuclear Antigen (PCNA) in Primary Hyperparathyroidism	nan	UNKNOWN
Calcitonin in Needle Wash Using Electrochemiluminescence Method For Diagnosis Of Medullary Thyroid Carcinoma.	nan	COMPLETED
Bone Markers and Bone Density Changes in Hyperperparathyroid Dialysis Patients Under Cinacalcet Treatment	nan	COMPLETED
Selective Activation of the Adrenomedullin Receptors in Migraine	nan	NOT_YET_RECRUITING
New Transporting Solution in Parathyroid Allotransplantation	nan	UNKNOWN
Calciotropic Effects After HCG Stimulation Test	nan	COMPLETED
The Effect of Disease-specific Treatment on Bone Turnover Markers in Patients With Primary Aldosteronism	nan	COMPLETED
The Effect of Cinacalcet on Gastric Acid Output in Healthy Subjects	nan	COMPLETED
Calcitonin for Treating X-linked Hypophosphatemia	nan	COMPLETED
Assessing Bone Calcium Content in Children With Kidney Disease Treated With Two Different Medicines	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a CALCR binder may also engage these)

Protein	Name	Similarity
Q63118	—	1.000	Q63118 →
O08893	—	1.000	O08893 →
A6QP74	—	1.000	A6QP74 →
Q9IB86	—	1.000	Q9IB86 →
Q68EK2	—	1.000	Q68EK2 →
P32214	—	1.000	P32214 →
P25117	—	1.000	P25117 →
P79222	—	1.000	P79222 →
Q60755	—	1.000	Q60755 →
Q0P4Y4	—	0.999	Q0P4Y4 →
Q7ZXS8	—	0.999	Q7ZXS8 →
Q8AXU4	—	0.998	Q8AXU4 →
VIPR2	Vasoactive intestinal polypeptide receptor 2	0.996	landscape →
CALCRL	Calcitonin gene-related peptide type 1 receptor	0.995	landscape →
O35659	—	0.995	O35659 →
Q9R1W5	—	0.995	Q9R1W5 →
P70205	—	0.995	P70205 →
Q8WN93	—	0.995	Q8WN93 →
P49190	—	0.994	P49190 →
GLP1R	Glucagon-like peptide 1 receptor	0.993	landscape →
Q90308	—	0.993	Q90308 →
Q29627	—	0.992	Q29627 →
Q28992	—	0.992	Q28992 →
Q5FWI2	—	0.992	Q5FWI2 →
P35000	—	0.992	P35000 →
Q95NQ0	—	0.992	Q95NQ0 →
P41588	—	0.991	P41588 →
Q91V95	—	0.991	Q91V95 →
P30083	—	0.991	P30083 →
P32215	—	0.990	P32215 →